Resmetirom is an oral medication that is taken in the form of tablets and falls within the category of receptor agonists. Thyroid gland Beta (THR-β), aims to reduce Fat accumulation In the liver and reduce its fibrosis (scarring). Patients with steatohepatitis Non-alcoholic syndrome (NASH) or similar illness.

In the United States, I agreed US Food and Drug Administration (FDA) approved this drug in 2024 to treat adults with non-alcoholic steatohepatitis (NASH) who have moderate to advanced fibrosis (but not complete cirrhosis).

For the European Union, it was issued European Medicines Agency (CHMP) expressed a positive opinion regarding the conditional authorization of this medicine in 2025.

The drug “Risemeterum” increases oxidation Fatty acids In the liver, it reduces lipogenesis, thereby reducing intrahepatic fat by selectively stimulating the THR-β receptor, which is mainly expressed in hepatocytes.

This mechanism may reduce liver inflammation and improve liver fibrosis. Clinical studies have shown that a higher percentage of patients who received this drug in the treatment group, compared to the placebo group, succeeded in reducing liver fat or improving liver fibrosis.

Currently, an Iranian knowledge-based company has produced this drug. It was unveiled at the first Far Iran exhibition, which began on November 2, 2025 at the Iranian International Fair and continues until the fifth.

Dr. Sina Dastani, Director of Marketing and Sales at this pharmaceutical company operating in the health sector, announced the first entry Chemical drug To treat non-alcoholic fatty liver to the pharmaceutical market in the country.

And he said:

This company’s technicians conducted extensive studies in conjunction with the main company producing this drug to produce it in the country.”

He added:

“The chosen product is of the highest scientific level in the world, and our team focused on the patient as the focus of the decision throughout all stages of its development. Fortunately, our efforts were crowned with success, and we were able to produce and market a drug to treat fatty liver, as the first country after the main company in the United States.”

He explained that the drug produced by this company is the first chemical drug in the world approved as a final treatment forFatty liver disease Non-alcoholic.

Dastani continued regarding the scientific advantages of this drug, saying:

“The scientific name of this drug is “resmetirom”. It is used for patients with non-alcoholic fatty liver disease with advanced degrees of fibrosis (from F2 to F3); that is, patients who show clear signs of fibrosis. Liver tissue damage in Transient elastography (TE), and they are medically qualified to receive this treatment.”

“Previously, there was no effective drug treatment for fatty liver disease, and patients relied mainly on herbal supplements or lifestyle modification methods,” Dastani noted.

Currently, this product is the only approved chemotherapy drug US Food and Drug Administration (FDA) and used directly to treat Fatty liver disease Non-alcoholic.

He continued, saying:

“The studies and production idea for this drug began about a year and a half ago, and after obtaining the necessary permits, this drug entered the Iranian pharmaceutical market during the past few months. It is currently available to patients in the country’s pharmacies.

“The feedback we received from patients regarding the effectiveness of this drug was very promising,” Dastani noted.

Dastani stressed the importance of this achievement in the country’s health system, saying:

“Fatty liver is one of the… Silent diseases Which affects at least 30% of the country’s population, and may lead to cirrhosis and liver failure if left untreated.

Producing this drug locally represents a major step towards reducing dependence on it from abroad and improving the level of treatment for Iranian patients.”